P/B
1,9
Avalo Therapeutics
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
$874.2M
Market Cap • 9/11/2026
2011
(15 years)
Founded
2015
(11 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
18,7
EPS
—
Market Cap
Market Cap
874,2M
EV
473,9M
EV/Revenue
0
EV/EBITDA
-5,2
EV/EBIT
-5,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-2,5%
Total Yield
-2,5%
Payout
0%
Retained Earnings
-504,5M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,1%
% Goodwill
2,1%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-100%
CAGR Op. Income 5Y
3,4%
CAGR Net Income 5Y
5,4%
CAGR EPS 5Y
-71,8%
CAGR OCF 5Y
1,4%
Leverage
N.D./EBITDA
4,4
Debt/Equity
0%
Current Ratio
19,3
Quick Ratio
18,9
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!